Session Details
[P]Hepadnaviridae
Mon. Nov 2, 2026 11:00 AM - 5:05 PM JST
Mon. Nov 2, 2026 2:00 AM - 8:05 AM UTC
Mon. Nov 2, 2026 2:00 AM - 8:05 AM UTC
Poster : Hepadnaviridae (2F Convention Hall AB)
[P-34]Mutational Removal of Hepatitis B Virus RNA m6A Methylations Reveal a Role in Viral RNA Stability and Replication
*Shania Foustine1, Pei-Yi (Alma) Su2,1, Chih-Hsu Chang1, Hsiu-Yi Wu1, Yuan-Ting Lee1, Kevin Tsai1,3 (1. Institute of Biomedical Sciences (IBMS), Academia Sinica, Taipei, Taiwan, 2. Department of Microbiology and Immunology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, 3. Institute of Microbiology, College of Medicine, National Taiwan University, Taipei, Taiwan)
[P-35]The role of ISG15 in the intracellular distribution of hepatitis B virus X protein
*Takayuki Abe1, Sameh A. Gad Hussein1, Lin Deng2, Ikuo Shoji2 (1. Niigata University , 2. Kobe University)
[P-36]Characterization of HBsAg Mutations Associated with Occult Hepatitis B Virus Infection Using HBV Replication and Baculovirus-Mediated Infection Models
*Yu-Hsuan Miao1, Yu-Han Su1, Chi-Wei Wang1, I-Chin Wu2, Chien-Ming Chiang2, Chih-Hsuan Tsai1 (1. Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, 2. Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan)
[P-37]Early occurrence of oncogenic hepatitis B virus integration in non-tumor liver tissues
*Kento Fukano1,2, Naganori Nao3, Akihito Tsubota4, Takae Toyoshima2, Azusa Kamikawa1, Haruyo Aoyagi2, Hideki Aizaki2, Masumichi Saito2, Kazuyoshi Hosomichi5, Takahiro Matsudaira6, Moto Kimura1, Koichi Watashi2, Masanori Isogawa2, Wataru Sugiura1, Masamichi Muramatsu7, Kousho Wakae2 (1. Center for Clinical Sciences, Japan Institute for Health Security, 2. National Institute of Infectious Diseases, Japan Institute for Health Security, 3. One Health Research Center, Hokkaido University, 4. Research Center for Medical Science, The Jikei University School of Medicine, 5. School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, 6. Biotechnological Research Support Division, FASMAC Co., Ltd., 7. Institute of Biomedical Research and Innovation, Foundation for Biomedical Research and Innovation at Kobe)
[P-38]Screening for HBV RNase H Inhibitors Using the RIKEN NPDepo Chemical Library
*Yutaka Furutani1, Tetsuya Toyoda2 (1. The Jikei University School of Medicine, 2. Fukushimura Hospital)
[P-39]Mechanistic Analysis of HBV Transcriptional Regulatory Region Suppression by Aripiprazole and Vorapaxar
*Atsuya Yamashita1, Hirotake Kasai1, Tomohisa Tanaka1,2, Yasunori Akaike1, Kohji Moriishi1,2 (1. Faculty of Medicine, Graduate Faculty of Interdi sciplinary Research, University of Yamanashi, 2. Division of Hepatitis Virology/Institute for Genetic Medicine/Hokkaido University)
[P-40]Construction of an In Vivo Drug Efficacy Model for Anti-HBV Compounds Using HBV-Producing Cells in TK-NOG Mice
*Haruyo Aoyagi1, Yutaka Furutani2, Kousho Wakae1, Kenji Ogawa3, Takashi Niwa4, Kaoru Kobayashi5, Takamitsu Hosoya6, Yousuke Kanayama7, Yuichiro Higuchi8, Hiroshi Suemizu8, Sumiko Nashi Nagoshi9, Tomokazu Matsuura2, Yasuyoshi Watanabe10, Masanori Isogawa1, Takaji Wakita1, Hideki Aizaki1 (1. Japan Institute for Health Security, 2. The Jikei University school of medicine, 3. Nihon University, 4. Kyushu University, 5. Meiji Pharmaceutical University, 6. Institute of Science Tokyo, 7. RIKEN Nishina Center for Accelerator-Based Science, 8. Central Institute for Experimental Medicine and Life Science, 9. Saitama Medical University, 10. RIKEN Center for Biosystems Dynamics Research)
[P-41]Major vault protein modulates HBV infection and provides a platform for the development of antiviral nanoparticles
*Xiang-Qing Lai1, Shih-Chi Wang2, Ke-Ji Lin2, Chun-Jen Liu2,3,4, Hui-Lin Wu1,2,3 (1. Graduate Institute of Microbiology, College of Medicine, National Taiwan University, Taipei, Taiwan, 2. Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan, 3. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, 4. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan)
[P-42]Comprehensive Identification of Regulatory Factors for the HBV EnhI-X Promoter Using an HSV1-TK/GCV Selection System
*Hirotake Kasai1, Atsuya Yamashita1, Tomohisa Tanaka1,2, Yasunori Akaike1, Kohji Moriishi1,2 (1. Dept. of Microbiology, Graduate School of Yamanashi University, 2. Institute for Genetic Medicine, Hokkaido University)
[P-43]Mechanistic and Structure–Activity Relationship Analyses of the Anti-HBV Activity of Gut Microbiota-Derived Menaquinone-4
*Ryo Fukushima1, Hirotake Kasai1, Atsuya Yamashita1, Tomohisa Tanaka1,2, Yasunori Akaike1, Kohji Moriishi1,2 (1. Department of Microbiology, Division of Medicine, Graduate Faculty of Interdisciplinary Research, University of Yamanashi, 2. Institute genetic Medicine, Hokkaido University)
[P-44]Onnamides A and B Suppress Hepatitis B Virus Transcription by Inhibiting Viral Promoter Activity
*Yasuhiro Hayashi1, Sei Arizono1, Nanami Higa2, Trianda Ayuning Tyas2, Kaiki Saito1, Yuichi Akahori4, Kenji Maeda4, Masaaki Toyama5, Kanami Mori-Yasumoto3, Mina Yasumoto-Hirose2, Kei Miyakawa5, Junichi Tanaka2, Takahiro Jomori2 (1. University of Miyazaki, 2. University of the Ryukyus, 3. Tokyo University of Science, 4. Kagoshima University, 5. National Institute of Infectious Diseases)
[P-45]Development of fluorine-containing compounds with anti-HBV activity
*Midori Takeda1, Satoshi Mizuta2, Nobuyuki Kato1, Takeshi Ishikawa3, Yasuhito Tanaka4, Masanori Ikeda1 (1. Joint Research Center for Human Retrovirus Infection, Kagoshima University, 2. Graduate School of Biomedical Sciences, Nagasaki University, 3. Graduate School of Science and Engineering, Kagoshima University, 4. Faculty of Life Sciences, Kumamoto University)
[P-46]V-001 Suppresses HBV Replication and Viral Antigen Synthesis, Combined with a Modified Targeted Delivery System
*xiaoquan liu1, ZhiPing Wan1, Hong Deng1 (1. Third Affiliated Hospital of Sun Yat-Sen University Guangzhou.)
[P-47]AMPK agonist MK-3903 suppresses HBV replication in an AMPK independent manner.
*Hironori Nishitsuji1, Takayuki Murata1, Kunitada Shimotohno2 (1. Fujita Health University School of Medicine, 2. Institute of Microbiology and Chemistry)
